GMAB: genmab.com Net earnings per share for the last 12 months

Symbol and logo of brand Genmab (GMAB)

Genmab A/S monetizes exclusive patents through high royalties from blockbuster sales. The change in rolling net income per share clearly confirms this strategy, with the latest parameter standing at 1.17. Growth is driven by alliances with pharma behemoths to accelerate therapy, while indirect pricing power shifts primary financial risks onto partners utilizing the company's unique antibodies.

GMAB (Genmab A/S) Net earnings per share (EPS TTM) history from 07/04/2022 to 11/10/2026

Analytical breakdowns for Genmab A/S

- share price and expert price forecast:
Stock Quotes Genmab A/S|GMAB - Fair Value Consensus
- market capitalization information:
Market Valuation Genmab A/S|GMAB - Aggregate Business Value
- balance sheet net asset value indicators:
Book Value per Share Genmab|GMAB - Book Capitalization|Market Value to Book Value Ratio genmab.com|GMAB - Aggregate Asset Value
- business debt structure and liquidity details:
Total Debt to Capital Genmab A/S|GMAB - Long-Term Indebtedness to Equity|Short-Term Debt to Capital Genmab US|GMAB - Company Cumulative Debt|Debt to Book Value Genmab A/S|GMAB - Amount of Long-Term Liabilities|Company Short-Term Debts Genmab|Quick Ratio genmab.com
- net income and valuation multiples indicators:
GMAB - Company Profit|Future Profit Genmab A/S|GMAB - Company Value to Net Income|Projected Price to Earnings Genmab|GMAB - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Genmab A/S|GMAB - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Genmab|GMAB - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months genmab.com|GMAB - Earnings per share increase in current year|Earnings growth forecast for next year Genmab A/S
Basic company analysis:Genmab A/S - GMAB
Manufactured products of Genmab AS

To objectively assess the operational efficiency of Genmab A/S, it is essential for investors to track the actual yield of each security. Fundamental net income per share TTM aggregates net income over the year and divides it by the number of shares, reflecting how successfully scientific freedom and oncological research are converted into financial results that determine the long-term value of the business.

Who Genmab A/S competes with

EXEL: Net earnings per share for the last 12 months|Earnings per share for the trailing year NUVL (nuvalent.com)|KYMR (Kymera) - Net earnings per share for the last 12 months|IDYA: Earnings per share for the last four quarters|ELVN (Enliven Pharma) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) ORIC Corp|Earnings per share for the last twelve months Relay Therapeutics (RLAY)|NRIX (nurixtx.com) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) TYRA (Tyra Biosciences)|Net earnings per share for the trailing year Verastem Oncology|Monte Rosa Tx - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Cullinan Corp|IMRX (Immuneering Corporation) - Net earnings per share for the last 12 months|CCCC: Earnings per share for the last four quarters|BDTX (Black Diamond Therapeutics) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Repare Therapeutics, Inc. RPTX|Net earnings per share (EPS TTM) PMVP|karyopharm.com - Earnings per share for the last 12 months|Propanc Biopharma - Net earnings per share for the last 12 months|Earnings per share for the trailing year BGMS|AADI: Net earnings per share for the last 12 months|Aileron Therapeutics - Earnings per share for the last four quarters|BPMC: Net earnings per share (EPS TTM)|GlycoMimetics - Earnings per share for the trailing year|SWTX (SpringWorks Therapeutics) - Net earnings per share (EPS TTM)